m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02855)
Name
CAP-232
Synonyms
TT-232; UNII-49D4Q4254Z; TT 232; 49D4Q4254Z; 147159-51-1; Phe-cys-tyr-trp-lys-cys-thr-NH2 (2-6)-disulfide; TLN 232; CAP-232; CAP 232; Phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-cysteinyl-threoninamide (2-6)-disulfide; AC1OCF7X; CHEMBL539934; TLN-232; L-Threoninamide, D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteinyl-, cyclic (2-6)-disulfide; TT2-32; ZINC169289417; AKOS024458270; DB12088; NCGC00249606-01
    Click to Show/Hide
Status
Phase 2a
Structure
3D MOL
2D MOL
Formula
C45H58N10O9S2
InChI
1S/C45H58N10O9S2/c1-25(56)38(39(48)58)55-45(64)37-24-66-65-23-36(53-40(59)31(47)19-26-9-3-2-4-10-26)44(63)51-34(20-27-14-16-29(57)17-15-27)42(61)52-35(21-28-22-49-32-12-6-5-11-30(28)32)43(62)50-33(41(60)54-37)13-7-8-18-46/h2-6,9-12,14-17,22,25,31,33-38,49,56-57H,7-8,13,18-21,23-24,46-47H2,1H3,(H2,48,58)(H,50,62)(H,51,63)(H,52,61)(H,53,59)(H,54,60)(H,55,64)/t25-,31-,33+,34+,35-,36+,37+,38+/m1/s1
InChIKey
SNAJPQVDGYDQSW-DYCFWDQMSA-N
PubChem CID
6918265
TTD Drug ID
D09EFC
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Pyruvate kinase M2 (PKM)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Pyruvate kinase M2 (PKM) is a therapeutic target for CAP-232. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of CAP-232 through regulating the expression of Pyruvate kinase M2 (PKM). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Pyruvate kinase M2 (PKM) is a therapeutic target for CAP-232. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CAP-232 through regulating the expression of Pyruvate kinase M2 (PKM). [2], [3]
Zinc finger CCCH domain-containing protein 13 (ZC3H13)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Pyruvate kinase M2 (PKM) is a therapeutic target for CAP-232. The Zinc finger CCCH domain-containing protein 13 (ZC3H13) has potential in affecting the response of CAP-232 through regulating the expression of Pyruvate kinase M2 (PKM). [2], [4]
References
Ref 1 m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation. Am J Transl Res. 2019 Sep 15;11(9):6084-6092. eCollection 2019.
Ref 2 TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. doi: 10.1093/nar/30.1.412.
Ref 3 YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis. Cell Death Dis. 2022 Mar 23;13(3):258. doi: 10.1038/s41419-022-04711-1.
Ref 4 ZC3H13 Inhibits the Progression of Hepatocellular Carcinoma through m(6)A-PKM2-Mediated Glycolysis and Enhances Chemosensitivity. J Oncol. 2021 Dec 30;2021:1328444. doi: 10.1155/2021/1328444. eCollection 2021.